Tryvio, aprocitentan
Named-patient access overview. Tryvio is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Tryvio
Tryvio (aprocitentan) is manufactured by Spero Therapeutics / GSK and indicated for hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients not adequately controlled on other drugs. It is an oral dual endothelin receptor antagonist (once-daily 12.5 mg tablet) approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Tryvio
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Tryvio for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Tryvio is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Tryvio in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Tryvio
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.